Patent: 10,485,796
✉ Email this page to a colleague
Summary for Patent: 10,485,796
Title: | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment |
Abstract: | The present invention provides, inter alia, a composition containing a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein. |
Inventor(s): | Saha; Saurabh (Wellesley Hills, MA), Zhang; Linping (Lexington, MA), Zhang; Xiaoyan Michelle (Lexington, MA) |
Assignee: | BIOMED VALLEY DISCOVERIES, INC. (Kansas City, MO) |
Application Number: | 15/809,759 |
Patent Claims: | see list of patent claims |
Details for Patent 10,485,796
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2035-06-29 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-06-29 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-06-29 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-06-29 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2035-06-29 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2035-06-29 |
Emd Serono, Inc. | BAVENCIO | avelumab | Injection | 761049 | 03/23/2017 | ⤷ Try a Trial | 2035-06-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |